Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | FENC |
---|---|---|
09:32 ET | 3298 | 4.69 |
09:34 ET | 100 | 4.47 |
09:36 ET | 100 | 4.505 |
09:54 ET | 2698 | 4.41 |
09:57 ET | 643 | 4.41 |
09:59 ET | 1121 | 4.43 |
10:01 ET | 100 | 4.41 |
10:08 ET | 2422 | 4.37 |
10:10 ET | 100 | 4.37 |
10:12 ET | 109 | 4.395 |
10:24 ET | 100 | 4.435 |
10:32 ET | 100 | 4.42 |
10:33 ET | 100 | 4.38 |
10:37 ET | 100 | 4.38 |
10:44 ET | 116 | 4.3801 |
10:57 ET | 100 | 4.38 |
11:00 ET | 2141 | 4.3701 |
11:06 ET | 100 | 4.37 |
11:08 ET | 100 | 4.37 |
11:13 ET | 100 | 4.37 |
11:20 ET | 300 | 4.37 |
11:56 ET | 100 | 4.42 |
12:21 ET | 1779 | 4.42 |
12:38 ET | 330 | 4.42 |
12:52 ET | 164 | 4.37 |
01:10 ET | 147 | 4.3701 |
01:42 ET | 644 | 4.37 |
01:48 ET | 1084 | 4.385 |
02:08 ET | 100 | 4.39 |
02:09 ET | 133 | 4.38 |
02:27 ET | 200 | 4.37 |
02:51 ET | 5544 | 4.35 |
03:00 ET | 620 | 4.36 |
03:02 ET | 184 | 4.36 |
03:05 ET | 200 | 4.35 |
03:07 ET | 100 | 4.34 |
03:43 ET | 1034 | 4.335 |
03:54 ET | 1500 | 4.35 |
03:56 ET | 400 | 4.395 |
03:57 ET | 522 | 4.38 |
03:59 ET | 9555 | 4.36 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Fennec Pharmaceuticals Inc | 122.3M | 112.1x | --- |
Werewolf Therapeutics Inc | 117.6M | -1.9x | --- |
TriSalus Life Sciences Inc | 116.7M | -2.3x | --- |
Elutia Inc | 108.0M | -1.1x | --- |
Adagene Inc | 139.5M | -3.9x | --- |
Aclaris Therapeutics Inc | 128.4M | -2.2x | --- |
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $122.3M |
---|---|
Revenue (TTM) | $48.9M |
Shares Outstanding | 27.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.25 |
EPS | $0.04 |
Book Value | $-0.43 |
P/E Ratio | 112.1x |
Price/Sales (TTM) | 2.5 |
Price/Cash Flow (TTM) | 44.7x |
Operating Margin | 12.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.